Yah BC kayaker ,

Jeepers I took my profits in BtI today and bought more shares of RVX  yikes 

Hopefully this is the cataylst of major institutions or fund managers to start there entry point into buy RVX shares,  Hopefully this continues with more psotive NR, ie    partnership deals....

I especially liek the qoute from DM  "It was shocking and highly encouraging to see the direct comparison of the protein data ranked by magnitude of effect in the two groups. For the first time, epigenetic and BET inhibition clinical data has been shown to differentially affect genes and proteins between advanced chronic kidney disease (CKD) patients and normal subjects," stated Donald McCaffrey, President and CEO.

First time i have ever seen a quote as "shocking ", is this a new approach or is it really shocking???

Advancing Can-Japan partnerships in #cancer #immunotherapy @BioJapan_ICS. Full house for #telestatherapeutics #zenithepigenetics seminar.

looks like Zenith Epigenetics presented in Japan at a seminar promoting Canadian Japanese biotech partnerships in October 2016

Hhmn I wonder if Takeda attended that seminar

Hart,

patience has its virtues, Roman was not built in a dAy and either is developing a drug from IND to passing phase 3 trials, it can easily take 20 years and RVX is at around 13 years with 2 more years to completion ,

If the assure trial post hoc analysis is proved not coincidence RVX will be a blockbuster and worth $5 to $10 billion,  I am willing to wait for that chance 

Many RVX investors and longs who closely follow the day to day business activities going on at Rvx would definitely be disappointed that the second license deal was not announced prior to the end of 2016 as I was.  

However ,  is it possible that negotiations with a small regional pharmaceutical company were going extremely when all of a sudden a large major BP came into the picture to buy everything including Zenith . At that point I would think Rvx management would not need a second regional deal if they going to be bought out from a BP and now negotiations  are ongoing right now.  A CVR type deal would be the best type for risk perspective for BP and they would u takin that $250 million tax credit as well,  just speculation but possible.

I also find it very interesting that from the notes from the AGM from either torpedoman or Fouremm from the betonmace trial  that management  know when MACE events occur ,  my thinking is that from the 2 DSMB reviews if the test group results were the same as the placebo group that they might for ethical reasons stop the trial .  Not sure it would be fair to have participants on such a long trial if it wasn't working to some degree

just another perceptive